Navigation Links
Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment
Date:4/2/2011

Berlin, Germany, Saturday 02 April 2011: Exciting new data presented today at the International Liver CongressTM 2011 show that quadruple therapy in chronic hepatitis C (HCV) patients suppressed the emergence of resistant variants and resulted in a 100% rate of sustained virological response - undetectable HCV RNA - 12 weeks after treatment (SVR12).1

In the quadruple therapy study, HCV patients were given four drugs in combination; pegylated Interferon-alpha (PegIFN-alpha); ribavirin (RBV); and two different direct-acting antivirals (DAAs) BMS-650032 (an HCV NS3 protease inhibitor) and BMS-790052 (an HCV NS5A replication complex inhibitor).

The current standard of care (SoC) for HCV therapy is PegIFN-alpha plus RBV a dual therapy. The addition of DAAs (currently in phase-III clinical trials) marks the next step in treatment evolution a triple therapy. However, the new data presented today suggests that quadruple therapy could be the next generation of treatment for chronic HCV patients.

Professor Heiner Wedemeyer, EASL'S Secretary General, said: "Quadruple therapy is possibly the future of HCV treatment; this study goes a way to confirming that. While it's expected that the first DAAs and triple therapy will be approved for use later this year, quadruple therapy appears to have a more profound effect on virological response, with less of a resistance problem."

The study may also provide new hope for a growing number of HCV patients who cannot be effectively treated for chronic hepatitis with current treatments.

The Phase-IIa trial looked at a cohort of 21 HCV genotype 1 null responders (patients who have failed to respond to previous treatment), of whom 19 had an unfavourable IL28B genotype, which predisposes HCV patients to treatment failure.

Only about 30% of null responders to PegIFN-alpha/RBV treatment achieve sustained virological response (SVR) when retreated with PegIFN-alpha/RBV plus telaprevir,
'/>"/>

Contact: Travis Taylor
easlpressoffice@cohnwolfe.com
44-784-306-9451
European Association for the Study of the Liver
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Insulin could be Alzheimers therapy
2. Early Brain Therapy May Help Movement in Dystonia Patients
3. New approach to leukemia chemotherapy -- is a cure in sight?
4. Benefits of Radiation Therapy Outweigh Risks of a Second Cancer: Study
5. New Therapy for Enlarged Prostate May Bypass Unpleasant Side Effects
6. For potentially crippling dystonia, earlier deep brain therapy gets better, quicker results
7. Scientists devise targeted therapy strategy for rare form of childhood cancer
8. FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma
9. Novel immunotherapy drug receives FDA approval for the treatment of metastatic melanoma
10. Interest in Toys May Predict Success of Autism Home Therapy
11. Short Course of Hormone Therapy Boosts Prostate Cancer Survival: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... CINCINNATIUsing the Department of Defense Serum Repository (DoDSR), University ... biomarkers for inflammatory bowel disease (IBD), which could help ... not yet shown symptoms. , This finding, the first ... MD, is being presented via podium presentation by staff ... Disease Week 2013, being held May 18-21 in Orlando, ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Today, Zane ... HSA and FSA accounts. Zane Benefits, which provides ... benefits, is the leader in defined contribution ... arrangements . , According to Zane Benefits’ website, the ... was signed into law in 2010 and impacts many ...
(Date:5/21/2013)... 2013 The American Diabetes Association ( ... the United States of America are affected with peripheral ... great risk of developing peripheral neuropathy which unfortunately makes ... ADA further goes on saying that the disease usually ... 2 million new cases are diagnosed every year in ...
(Date:5/21/2013)... Reporter , , TUESDAY, May 21 (HealthDay News) -- Swollen ... apnea in children, and while removing them did not ... did help them with sleep, behavior and quality of ... a condition that causes abnormal pauses in breathing during ... with the surgery, and those improvements were likely responsible ...
(Date:5/21/2013)... In adults with chronic kidney disease (CKD), cigarette ... progression and transplant failure. Now, a first-of-its-kind study by ... has found a possible similar effect in children with ... , The study of 366 children aged 1 to ... of secondhand smoke exposure in CKD, according to lead ...
Breaking Medicine News(10 mins):Health News:Biomarkers discovered for inflammatory bowel disease 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 2Health News:Removing Tonsils Helps Kids With Sleep Apnea, Study Finds 3Health News:Exposure to Secondhand Smoke May Lead to Worsening of Pediatric Kidney Disease; Pediatric Nephrology Publishes Dayton Children’s, Johns Hopkins Joint Study 2Health News:Exposure to Secondhand Smoke May Lead to Worsening of Pediatric Kidney Disease; Pediatric Nephrology Publishes Dayton Children’s, Johns Hopkins Joint Study 3
... men enrolled in an active surveillance program for prostate ... fared just as well as men who opted to ... during surveillance showed high-grade cancer. Active surveillance, or ... tumors are considered small, low-grade and at low risk ...
... A psychological intervention program designed for breast cancer patients reduces ... shows. The study is the latest in a series ... program that teaches patients how to cope with the disease ... survival. Researchers at Ohio State,s Comprehensive Cancer Center had ...
... guidelines for best treatment practices are common, they ... to them in clinical practice, according to a ... medicine researchers. In the study, UC associate ... his colleagues used national standards for treatment of ...
... -- City of Hope researchers received approval from the ... first-in-human study of a neural stem cell-based therapy targeting ... tumor. Karen S. Aboody, M.D., associate professor in City ... that developed this treatment strategy. Jana Portnow, M.D., assistant ...
... the University of Cincinnati (UC) and the Cincinnati ... received funding to study the care processes that ... beginning dialysis. Timmy Lee, MD, UC Health ... the study, was awarded the National Kidney Foundation,s ...
... cats have them and whales have some, too. Neurons, those ... our spinal cords to the tips of our toes, paws ... journal Cell , scientists from the Harvard Medical School, ... found a new way by which nerve cells relay information ...
Cached Medicine News:Health News:Delay in surgery not likely to worsen tumors in men with low-risk prostate cancer 2Health News:Intervention program helps breast cancer patients live longer after recurrence 2Health News:Intervention program helps breast cancer patients live longer after recurrence 3Health News:'Knowledge translation' keeps treatment current 2Health News:FDA approves first human neural stem cell clinical trial to treat brain tumors 2Health News:FDA approves first human neural stem cell clinical trial to treat brain tumors 3Health News:New research examines care practices in place for dialysis patients 2
(Date:5/21/2013)... SANTA CLARA, Calif. , May 21, ... a game-changing embedded-ultrasound platform, today announced the ... Toolkit that allows complete network-based communications with ... demonstrate its latest embedded-ultrasound technology, including this ... Sao Paulo, Brazil ...
(Date:5/21/2013)... , May 21, 2013 Hurel Corporation ... and microfluidic cell-based assay platforms, today announced the appointment ... DABT to the Company,s Board of Directors. Dr. MacDonald ... of the Schering-Plough Research Institute ("SPRI"), which was the ... acquisition by Merck & Co. in 2009. ...
(Date:5/21/2013)... -- Vasomedical, Inc. (OTC BB: VASO) (the "Company"), a diversified medical ... medical devices and in the domestic sale of diagnostic imaging ... , President and CEO of Vasomedical, Inc. will present at ... 30, 2013 in New York City ... presentation is scheduled to begin at 9:30 a.m. EDT. ...
Breaking Medicine Technology:Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2
... 2012  Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company ... technologies in the field of transplantation therapy for patients ... technology from Yale University. "In the ... Herold and his colleagues at Yale University School of ...
... /PRNewswire-iReach/ -- PharmacyGPO, Inc.,  a ... the United States, today announced a three-year agreement ... (Photo: http://photos.prnewswire.com/prnh/20120507/CG01217 ) ... Smith, a leading national wholesaler, will be the ...
Cached Medicine Technology:Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 2PharmacyGPO Buying Group Selects H. D. Smith as Primary National Distributor 3
Suture Cutter, straight...
Suture Cutter, 15 Up Curve...
Suture scissor...
...
Medicine Products: